PMID: 15220241Jun 29, 2004Paper

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

Diabetes Care
Bernard CharbonnelPROactive Study Group

Abstract

The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) assesses the effect of pioglitazone, a peroxisome proliferator-activated receptor agonist, with anti-inflammatory and vascular properties, on the secondary prevention of macrovascular events in type 2 diabetes. PROactive is an on-going randomized, double-blind outcome study in patients with type 2 diabetes managed with diet and/or oral blood glucose-lowering drugs (combination of oral agents with insulin is permitted) who have a history of macrovascular disease. Patients are randomized to receive pioglitazone (forced titration from 15 to 30 to 45 mg, depending on tolerability) or placebo in addition to existing therapy. The primary end point is the time from randomization to occurrence of a new macrovascular event or death. Follow-up is estimated to span 4 years. A total of 5238 patients have been randomized from 19 countries. At entry into the study, patients enrolled are a mean age of 61.8 years, with type 2 diabetes for a mean of 9.5 years; 60.9 and 61.5% are taking metformin or a sulfonylurea, respectively; and 33.6% are using insulin in addition to oral glucose-lowering drugs. The majority of patients are men (66.1%). Patients are required to m...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Apr 11, 1996·The New England Journal of Medicine·J P DesprésP J Lupien
Jul 1, 1996·Diabetes Research and Clinical Practice·G Schernthaner
Oct 15, 1996·The Journal of Clinical Investigation·R E LawW A Hsueh
Feb 1, 1996·American Journal of Hypertension·J D PeulerM J Hodorek
May 20, 1998·The Journal of Clinical Endocrinology and Metabolism·J MinamikawaH Koshiyama
Aug 26, 1998·The Journal of Clinical Endocrinology and Metabolism·J YipG M Reaven
Aug 23, 2000·The Journal of Clinical Investigation·J M Olefsky
Aug 15, 2001·Circulation·R Fox
Oct 5, 2001·Metabolism: Clinical and Experimental·T NakamuraH Koide
Dec 18, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·W A Hsueh, R E Law
Feb 7, 2003·Journal of Human Hypertension·G BakrisM I Freed
May 15, 2003·International Journal of Experimental Diabesity Research·Shimon Efrat
Jun 27, 2003·Drugs·Michaela Diamant, Robert J Heine
Dec 18, 2003·The American Journal of Medicine·Gabriel I Uwaifo, Robert E Ratner
Dec 18, 2003·The American Journal of Medicine·David S H Bell
Dec 18, 2003·The American Journal of Medicine·Christopher J Lyon, Willa A Hsueh
Apr 19, 2005·Treatments in Endocrinology·Burkhard Göke, UNKNOWN German Pioglitazone Study Group

❮ Previous
Next ❯

Citations

Feb 25, 2005·Current Atherosclerosis Reports·Robert Chilton, Elaine Chiquette
Feb 3, 2005·Current Atherosclerosis Reports·Brandy PanuntiVivian Fonseca
Feb 5, 2009·Current Diabetes Reports·Stuart W Zarich
Apr 29, 2010·Current Diabetes Reports·Stuart W Zarich
Jan 13, 2006·Current Treatment Options in Cardiovascular Medicine·Helen M Colhoun, David John Betteridge
Dec 17, 2008·Biochemical and Biophysical Research Communications·Kazuo FujisawaEiichi Araki
Mar 23, 2005·Current Opinion in Pharmacology·Anders Berkenstam, Jan-Ake Gustafsson
Mar 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Klaus PollingerAchim Goepferich
Apr 27, 2010·European Heart Journal·Raffaele De Caterina, Rosalinda Madonna
Mar 18, 2010·BMC Clinical Pharmacology·Isabel PüntmannBernd Mühlbauer
Aug 13, 2010·Osteopathic Medicine and Primary Care·Allison M Petznick, Jay H Shubrook
Jun 12, 2012·Journal of Lipid Research·Janice V HuangGregory G Schwartz
Dec 7, 2007·Journal of the American Society of Nephrology : JASN·Christian A SchneiderErland Erdmann
Nov 18, 2010·Journal of Atherosclerosis and Thrombosis·Takashi HitsumotoKohji Shirai
Sep 3, 2011·Southern Medical Journal·Karen R SandoJames Taylor
Nov 24, 2007·Pharmacogenomics·Sharon Cresci
Jan 1, 2008·PPAR Research·Raghu Vemuganti
Jul 23, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jean-Luc FaillieDominique Hillaire-Buys
Jul 29, 2009·Nature Reviews. Endocrinology·Stuart W Zarich
Jul 31, 2010·Expert Review of Cardiovascular Therapy·Pedro de Pablos-Velasco
Mar 7, 2012·Expert Review of Cardiovascular Therapy·Christine KoulisTerri J Allen
Aug 22, 2006·Expert Review of Cardiovascular Therapy·Andreas PfütznerThomas Forst
Mar 1, 2006·Expert Opinion on Pharmacotherapy·Andreas Pfützner, Thomas Forst
Aug 19, 2007·Expert Opinion on Pharmacotherapy·Andreas PfütznerThomas Forst
Aug 23, 2005·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·Gerit-Holger Schernthaner, Guntram Schernthaner
Apr 3, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·John DormandyUNKNOWN PROactive investigators
Jun 18, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael BodmerChristoph R Meier
Jun 22, 2013·Diabetes & Metabolism·M P HermansM F Rousseau
Jun 27, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·W J ValentineUNKNOWN PROactive Study Group
Oct 2, 2012·Diabetes Research and Clinical Practice·André J Scheen
Feb 24, 2012·Revista Española De Cardiología·Rosalinda Madonna, Raffaele De Caterina
Oct 17, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Christian Lerch, Bernd Richter

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.